The first evidence-based consensus statement on tumor immunotherapy for the treatment of patients with melanoma was released by the Society for Immunotherapy of Cancer (SITC) and published online by Nature Reviews Clinical Oncology in 2013.
"The Society for Immunotherapy of Cancer Consensus Statement on Tumor Immunotherapy for the Treatment of Cutaneous Melanoma," offers a road map for using immunotherapy to treat patients with melanoma.
This consensus statement provides patients and physicians with expert evidence-based recommendations for the use of immunotherapies including interferon-α2, pegylated interferon, interleukin-2 (IL-2) and ipilimumab. This statement includes recommendations for patient selection, toxicity management, clinical end points, and sequencing or combination of therapies.
The Melanoma Research Foundation worked directly with SITC leadership to create an educational video about the Guidelines, published in 2013.
The Cancer Immunotherapy Guidelines-Melanoma manuscript is currently being updated. All members of the 2011 – 2013 Task Force and Steering Committee, as identified below, have returned to lead this project.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com